SCHEMBL6791830

SCHEMBL6791830

CCOC(=O)c1cc(NC(=O)NC)ccc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.56
LMNA P02545 1/20 0.49
TRPV1 Q8NER1 2/20 0.41
ALDH1A1 P00352 3/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
POLB P06746 1/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783765 0.93 TERT (0.59) TERTLMNATRPV1ALDH1A1CA12
SCHEMBL6786590 0.89 TERT (0.55) TERTLMNATRPV1ALDH1A1CA12
SCHEMBL6786810 0.87 TERT (0.71) TERTPOLBKMT2AKDM4ENPC1
SCHEMBL6791907 0.87 TERT (0.50) TERTLMNATRPV1ALDH1A1KMT2A
SCHEMBL6788362 0.86 TERT (0.53) TERTLMNAALDH1A1CA12CA1
SCHEMBL6788177 0.86 TERT (0.55) TERTLMNAALDH1A1CA12CA1
SCHEMBL6784598 0.84 TERT (0.53) TERTLMNAALDH1A1CA12CA1
SCHEMBL6784867 0.84 TERT (0.55) TERTLMNAALDH1A1KMT2ACYP1A2
SCHEMBL6784141 0.83 TERT (0.58) TERTLMNAALDH1A1KDM4ECYP1A2
SCHEMBL6784482 0.82 TERT (0.53) TERTLMNAALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885LMNA 169/4885TRPV1 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.